As global biotech investment patterns shift, investors are turning their eyes to Asia-Pacific. While China remains a powerhouse, emerging hubs like Singapore and South Korea are quickly gaining attention for their political stability, strong IP protection, and innovation-friendly policies.
Why are APAC biotech markets suddenly so appealing to investors? And how are these emerging hubs reshaping the future of global biotech innovation?
On Wealth Tracker, Hongbin Jeong speaks to Fabio La Mola, Partner at Bain & Company, to find out more.

Budget 2026: Did this year's Budget hit the mark for young Singaporeans?
19:46

Wealth Tracker: How is gold and silver reacting to US inflation and China demand?
12:44

What's Trending: Singapore wants you to stop gambling with blind boxes... and is Lunar New Year turning cyber?
18:07